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1007. It has long been recognized that patients with diabetes pose a particularchallenge to cardiologists and cardiovascular surgeons. Patients with dia-betes have worse outcomes after acute myocardial infarction,1 have a moreominous outlook if congestive heart failure develops, and appear to be atincreased risk for serious arrhythmias and sudden cardiac death.2 Com-pounding these problems is the fact that patients with diabetes may have
more advanced, diffuse coronary disease, making interventional procedures or
coronary artery bypass grafting (CABG) unattractive, or they may have end-organ
renal or neurologic dysfunction that excludes them from other therapies, such as
cardiac transplantation. Outcomes of patients with diabetes who undergo surgical
revascularization have been shown to be inferior to those of their counterparts
without diabetes.3 Any strategy that could improve outcomes in this group of
patients would be a welcome addition to our surgical armamentarium.
In this issue of the Journal, Furnary and colleagues4 present a study of insulin
management in patients who had undergone CABG. During a 15-year period, their
management of glucose levels was altered from a protocol of intermittent subcuta-
neous insulin injections to one of continuous intravenous insulin infusion. Another
important evolution was in the target serum glucose levels for these patients, a value
that moved from 200 mg/dL to 100 mg/dL during the study interval. Associated with
these changes in glucose and insulin management were significant improvements in
outcomes. Operative mortality was significantly reduced, with the principal benefit
accounted for by an improvement in cardiac-related mortality. Furnary and col-
leagues4 theorize that the mechanism of this effect is related to improved glucose
uptake and use by the heart, leading to a superior metabolic condition within the
myocyte and subsequent improved postischemic cardiac performance.
The concept that glucose and insulin management are important in myocardial
ischemia is not new. More than 40 years have elapsed since the report of Sodi-
Pollares and associates5 describing a beneficial effect of an intravenous infusion of
glucose, insulin, and potassium (GIK) on the electrophysiologic signs of myocardial
infarction. A large number of experimental studies and clinical trials have been
published since then, many showing a reduction in infarct size and improved
survival in patients treated with this “metabolic cocktail.” Not all studies of GIK
have shown a benefit, however, and the use of this treatment modality is far from
universal today. One feature that may contribute to these conflicting results is the
use of different GIK regimens. To achieve meaningful metabolic results, a mixture
of 30% glucose, 50 units of insulin, and 80 mmol of potassium delivered at a rate
greater than 1.5 mL/(kg  h) may be required.6 In addition, it should be noted that
the vast majority of GIK studies have involved patients without diabetes. Patients
with diabetes have impaired glucose uptake and increased plasma levels of free fatty
acids during ischemia, conditions that increase their susceptibility to myocardial
damage after ischemia. The Diabetes Insulin-Glucose in Acute Myocardial Infarc-
tion trial is the largest study to date to examine the effect of a similar metabolic
strategy in patients with diabetes. It found a significant benefit of an insulin-glucose
infusion as an adjunctive therapy for acute myocardial infarction.7 The rationale for
further study of insulin therapy in patients with diabetes who undergo CABG
therefore seems particularly timely.
It may seem intuitively obvious that better glucose management can improve the
outcomes of patients with diabetes undergoing CABG. Latham and colleagues8 have
shown that tighter glycemic control is associated with a reduction in wound
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infections after CABG, and higher glucose levels have been
suggested to have an adverse effect on central nervous
system morbidity after surgical revascularization. This
study by Furnary and colleagues4 did not specifically ad-
dress these postoperative complications, although this group
has previously reported a reduction in deep sternal wound
infections with their continuous intravenous insulin proto-
col.9 They did identify a significant mortality benefit that
appeared to be related to cardiac events after surgery, in
particular low cardiac output and left ventricular failure. As
a result, Furnary and colleagues4 have concluded that tighter
perioperative glucose management reduced mortality
through improvements in myocardial metabolism after isch-
emia.
Abundant experimental data have accumulated to sup-
port this hypothesis. Insulin leads to increased glucose up-
take by the heart, providing more substrate for glycolytic
adenosine triphosphate (ATP) production during ischemia.
Insulin may also increase pyruvate dehydrogenase activity,
thereby improving oxidation of glucose and lactate during
reperfusion and suppressing oxidation of fatty acids, which
can be harmful to the postischemic heart. A significant
correlation between glucose levels and mortality, as ob-
served in this study, would seem to support this concept.
However, the idea that altering insulin management and
controlling hyperglycemia will improve results of CABG
through this metabolic mechanism is not established by
these results. The study provides an intriguing concept, but
further investigations will be needed before we can com-
pletely understand why mortality is reduced with this pro-
tocol.
First, we need to gain a much greater understanding of
the fate of glucose within the myocyte. Under normal con-
ditions, glucose plays a relatively minor role in myocardial
energy metabolism. Fatty acids are the major oxidative fuel
used by the heart, accounting for 60% to 100% of myocar-
dial oxygen consumption, with much lesser contributions
from lactate and glucose. During ischemia, catabolism of
glucose through the glycolytic pathway yields a relatively
small amount of ATP compared with complete oxidation
through the citric acid cycle, yet glycolytically derived ATP
may have special significance. Experimental evidence sug-
gests that glycolytically derived ATP is preferentially used
for calcium reuptake by sarcoplasm reticulum, an essential
process for diastolic relaxation.10 Glycolytically derived
ATP preferentially inhibits cardiac ATP-sensitive potas-
sium channels and is important for the optimal function of
the sodium-potassium ATPase to prevent intracellular so-
dium accumulation during ischemia. Under aerobic condi-
tions, manipulations that increase oxidation of glucose will
increase acetyl coenzyme A levels. This can lead to a
reciprocal decrease in oxidation of fatty acids, probably
from an increase in malonyl coenzyme A production with a
subsequent inhibition of carnitine palmityl transferase 1
activity. Strategies that switch cardiac metabolism from
fatty acids to carbohydrate fuels are usually found to have
beneficial effects on postischemic recovery.
But do these metabolic events occur in cardiac surgical
patients treated with insulin, as outlined by Furnary and
colleagues?4 We simply do not have enough information to
know. Furnary and colleagues4 have not provided any data
on levels of insulin, free fatty acids, intracellular metabo-
lites, myocardial ATP levels, enzyme activity levels, or
glycolytic rates. As a result, we must be cautious in attrib-
uting the beneficial effects to primary alterations in cardiac
metabolism. Most of the experimental work defining the
effects of glucose and insulin has been done on animal
models that were not diabetic, making assumptions about
mechanisms even more speculative.
Metabolism in the heart is altered by ischemia, and
during ischemia glucose metabolism is slowed and confined
to anaerobic (glycolytic) pathways. Although glycolytically
derived ATP may be beneficial during ischemia under some
experimental conditions, ultimately this process will lead to
lactate accumulation and progressive intercellular acidosis.
Neely and Grotyohann11 have shown that depletion of gly-
cogen before myocardial ischemia is actually protective,
presumably by reducing glucose metabolism and lactate
accumulation. Thus glucose loading and subsequent glucose
use during ischemia may be beneficial or deleterious, de-
pending on the particular conditions encountered. In pa-
tients undergoing heart surgery, we rarely have enough
information of their metabolic state to postulate whether an
intervention that is dependent on these factors will lead to
successful, deleterious, or indifferent outcomes.
The authors of this study in the Journal show a strong
relationship between lower serum glucose levels (tighter
glucose control) and mortality during a 15-year period. The
implication here is that improved insulin protocols move
glucose into the heart cells to beneficially alter cardiac
metabolism. Again, we must be cautious with this interpre-
tation. Insulin administration results in reduction of blood
glucose levels primarily by movement of glucose into tis-
sues other than the heart. More than 30 years ago Curtis-
Prior and colleagues12 measured the contributions of differ-
ent organs and tissues of the rat to the assimilation of
glucose. The vast majority of glucose was taken up by
skeletal muscle, skin, adipose tissue, and liver. Only a small
fraction (less than 1%) was taken up by the myocardium.12
In addition, patients with diabetes may have impaired myo-
cardial glucose uptake, further skewing the relationship
between serum glucose levels and cardiac metabolism. Re-
cent studies have suggested that the relationship of admin-
istered insulin, cardiac glucose uptake, and ischemic toler-
ance may be even more complex. One recent report found
that insulin-mediated cardioprotection was independent of
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the presence of glucose at reperfusion.13 McNulty14 has
shown that any increase in myocardial glucose extraction in
response to systemic insulin is mediated as much by a
reduction in circulating free fatty acids as by direct insulin
action on the heart itself. Perhaps we should be monitoring
free fatty acid levels instead of glucose levels in these
patients.
Finally, the method of myocardial protection used for the
patients in this study was intermittent fibrillation without the
use of cardioplegia. This is a distinctly uncommon mode of
myocardial protection for most surgeons today, and one that
may more closely approximate the global ischemic models
on which the potential metabolic mechanism is based. Sur-
geons who incorporate hypothermia or potassium cardiople-
gia into their myocardial protective techniques may already
be achieving some of the metabolic effects that are attrib-
uted to tighter insulin control, because both hypothermia15
and potassium arrest16 have been experimentally demon-
strated to alter myocardial substrate metabolism by sup-
pressing fatty acid oxidation. Those who use warm contin-
uous cardioplegia or off-pump techniques may be further
limiting episodes of myocardial ischemia and as a result
may not derive benefits of the magnitude observed in this
study.
Nevertheless, the results presented by Furnary and col-
leagues4 for patients with diabetes are excellent and intrigu-
ing. Surgeons may find their insulin protocol to be a useful
guide to incorporate in their own practices for these chal-
lenging patients. More work will be needed to elucidate the
underlying mechanisms behind their observations. As we
learn more about the metabolic consequences of insulin on
postischemic cardiac glucose and fatty acid oxidation, we
should be able to generate refinements in myocardial pro-
tective strategies that can take advantage of these mecha-
nisms. This should ultimately lead to further improvements
in the results of CABG for patients with diabetes. And that
may be the sweetest result of all.
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